Elan may now be delivering an operating profit, but third quarter results last week gave investors every reason to continue to be cautious about the drugs company.
Elan’s main source of revenue at present is the multiple sclerosis (MS) drug Tysabri, accounting for 77 per cent of income in the quarter. The rest comes from the Elan Drug Technologies division (EDT), but Elan is likely to spinoff this operation at some stage, having already considered...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Unlimited Access for 2 Years
Get a Business Account for you and your team